<section id="landing-page">
    <div class="hero">
        <img src="assets/images/hero.png" alt="A man solving a puzzle with a little girl" />
        <div class="cta">
            <h1>When<br>
                <span class="extrabold">Peripheral T-Cell Lymphoma</span><br>
                returns<br>
                <span class="extrabold">BELEODAQ</span> may fit into your<br>
                <span class="extrabold">treatment plan</span>
            </h1>
        </div>
    </div>
    <h4 class="semibold secondary">BELEODAQ is a prescription medicine used to treat adults with a type of cancer called peripheral T-cell lymphoma (PTCL) that has come back (relapsed) or does not respond to previous treatment (refractory).<sup>1</sup></h4>
    <h2><span class="extrabold">BELEODAQ</span> may be an option for you</h2>
    <p>Your doctor may have talked with you about treatment with <span class="semibold secondary">BELEODAQ</span>, and you may be looking for more information to see if it is right for you. Or you may be researching possible treatment options on your own.</p>
    <p>This website will tell you about how <span class="semibold secondary">BELEODAQ</span> works, what it may be like to take <span class="semibold secondary">BELEODAQ</span>, and what to expect as you go through treatment. Here are a few of the main reasons to consider <span class="semibold secondary">BELEODAQ</span>:</p>
    <div class="grad-box">
        <h2>BELEODAQ has helped patients with relapsed or refractory PTCL</h2>
        <p><span class="semibold secondary">BELEODAQ</span> is an FDA-approved, single-agent treatment that has been shown to be effective in stopping cancer cells from growing in relapsed or refractory PTCL.<sup>1</sup></p>
        <a href="">Learn more about the clinical trial results for BELEODAQ</a>
    </div>
    <div class="grad-box">
        <h2>BELEODAQ is well tolerated</h2>
        <p>In clinical studies, most patients who received <span class="semibold secondary">BELEODAQ</span> had side effects that were generally mild to moderate in severity. The most common side effects were nausea, fatigue, fever, anemia, and vomiting.<sup>1,2</sup></p>
        <a href="">Learn more about the possible side effects with BELEODAQ</a>
    </div>
    <div class="grad-box">
        <h2>BELEODAQ may fit your daily routine</h2>
        <p><span class="semibold secondary">BELEODAQ</span> is given in a 3-week cycle that includes 5 consecutive days of active treatment with a 30-minute intravenous (IV) infusion each day, followed by 16 days off treatment. With a short, 30-minute infusion on days 1 through 5, you may have time to fit additional activities that are important to you into your day.<sup>1</sup></p>
        <a href="">Learn more about how to take BELEODAQ</a>
    </div>
    <a href="" class="next-btn">Next: What Is BELEODAQ, and How Does It Work? <i class="fas fa-chevron-right"></i></a>
</section>